Elizabeth Arnold
About Elizabeth Arnold
Elizabeth Arnold is the Executive Director and Commercial Lead for Orencia at Bristol Myers Squibb, with extensive experience in oncology, haematology, and virology within the pharmaceutical industry.
Company
Elizabeth Arnold is currently with Bristol Myers Squibb, operating out of Princeton, New Jersey, United States. She serves as the Executive Director, Commercial Lead for Orencia, a medication used to treat autoimmune diseases. She previously held multiple roles within the company, emphasizing her expertise in the pharmaceutical and healthcare markets.
Previous Titles
Elizabeth Arnold has held significant roles at Bristol Myers Squibb, including Director, Strategy & Operations, US CV & Established Brands (2021-2022), and Director, Worldwide Oncology Commercialization – HCC/Pancreas (2020-2021). Prior to these roles, she gained experience as a Market Analyst at Coles Myer in Melbourne, Australia, and as a Research Assistant at Monash Business School.
Education and Expertise
Elizabeth Arnold has an extensive academic background from Monash University, where she earned a Bachelor of Science, a Bachelor of Commerce (BCom) in Economics & Marketing, and a Post Graduate Certificate in Health Economics. She furthered her qualifications at INSEAD, focusing on Organizational Leadership and achieving Managerial Excellence. Her education has equipped her with specialized knowledge in health economics, marketing, and financial reporting.
Career Background
Elizabeth Arnold's career spans various domains within the pharmaceutical and healthcare industries. Notably, she led the US Sales & Marketing for Orencia, demonstrating her capability in pre-launch planning and health economics & pricing. Her collaborative efforts with cross-functional teams and agencies underscore her leadership style and her focus on performance and results.
Regulatory Knowledge
Elizabeth Arnold possesses strong knowledge of regulatory bodies such as the Pharmaceutical Benefits Advisory Committee (PBAC), Therapeutic Goods Administration (TGA), and the Medicines Australia Code of Conduct. Her understanding of these regulatory frameworks is crucial for navigating the complex environments of Oncology, Haematology, and Virology within highly regulated markets.